GlaxoSmithKline-backed RegenXBio filed for its initial public offering last month when it expected to raise up to $100m.
US-based gene therapy developer RegenXBio, backed by pharmaceutical company GlaxoSmithKline (GSK), priced its initial public offering on Nasdaq at $140m, putting up 6.4 million shares at $22 each.
The company began trading yesterday and shares climbed to more than $30. RegenXBio had filed for a flotation last month, when it expected to secure up to $100m in proceeds.
The company was co-founded by research firm Foxkiser, University of Pennsylvania and James Wilson, who now serves as chief scientific advisor. RegenXBio…
